JP7905369B2 - 腎臓活性融合タンパク質及びそれを使用する治療方法 - Google Patents
腎臓活性融合タンパク質及びそれを使用する治療方法Info
- Publication number
- JP7905369B2 JP7905369B2 JP2023572788A JP2023572788A JP7905369B2 JP 7905369 B2 JP7905369 B2 JP 7905369B2 JP 2023572788 A JP2023572788 A JP 2023572788A JP 2023572788 A JP2023572788 A JP 2023572788A JP 7905369 B2 JP7905369 B2 JP 7905369B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- fusion protein
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- External Artificial Organs (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025086967A JP2025116068A (ja) | 2021-05-25 | 2025-05-26 | 腎臓活性融合タンパク質及びそれを使用する治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192835P | 2021-05-25 | 2021-05-25 | |
| US63/192,835 | 2021-05-25 | ||
| PCT/US2022/030658 WO2022251168A1 (en) | 2021-05-25 | 2022-05-24 | Kidney active fusion proteins and methods of treatment using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025086967A Division JP2025116068A (ja) | 2021-05-25 | 2025-05-26 | 腎臓活性融合タンパク質及びそれを使用する治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024520421A JP2024520421A (ja) | 2024-05-24 |
| JP2024520421A5 JP2024520421A5 (cg-RX-API-DMAC7.html) | 2025-06-04 |
| JP7905369B2 true JP7905369B2 (ja) | 2026-08-14 |
Family
ID=84230212
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572788A Active JP7905369B2 (ja) | 2021-05-25 | 2022-05-24 | 腎臓活性融合タンパク質及びそれを使用する治療方法 |
| JP2025086967A Pending JP2025116068A (ja) | 2021-05-25 | 2025-05-26 | 腎臓活性融合タンパク質及びそれを使用する治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025086967A Pending JP2025116068A (ja) | 2021-05-25 | 2025-05-26 | 腎臓活性融合タンパク質及びそれを使用する治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240262877A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4347666A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7905369B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240013770A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117396519A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022283254A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024627A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177162A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308754A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014037A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022251168A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116472065A (zh) * | 2020-10-05 | 2023-07-21 | 阿雷克森制药公司 | 治疗皮肌炎的方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003527115A (ja) | 2000-03-13 | 2003-09-16 | セント ビンセンツ ホスピタル | 新規のh因子関連タンパク質5及びその抗体 |
| JP2013520979A (ja) | 2010-03-05 | 2013-06-10 | リグショスピタレト | 補体活性化のキメラ抑制分子 |
| WO2018075462A1 (en) | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating and preventing transplant-associated injury |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5250548B2 (ja) * | 2006-06-21 | 2013-07-31 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 疾患の治療のための補体h因子の標的化 |
| EP3033093A1 (en) * | 2013-08-16 | 2016-06-22 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
| WO2020041644A1 (en) * | 2018-08-22 | 2020-02-27 | Alexion Pharmaceuticals, Inc. | Fusion proteins and methods of treating complement dysregulation using the same |
-
2022
- 2022-05-24 AU AU2022283254A patent/AU2022283254A1/en active Pending
- 2022-05-24 WO PCT/US2022/030658 patent/WO2022251168A1/en not_active Ceased
- 2022-05-24 IL IL308754A patent/IL308754A/en unknown
- 2022-05-24 EP EP22811954.1A patent/EP4347666A4/en active Pending
- 2022-05-24 BR BR112023024627A patent/BR112023024627A2/pt unknown
- 2022-05-24 MX MX2023014037A patent/MX2023014037A/es unknown
- 2022-05-24 JP JP2023572788A patent/JP7905369B2/ja active Active
- 2022-05-24 KR KR1020237044189A patent/KR20240013770A/ko active Pending
- 2022-05-24 CN CN202280035932.2A patent/CN117396519A/zh active Pending
- 2022-05-24 CA CA3177162A patent/CA3177162A1/en active Pending
- 2022-05-24 US US18/561,469 patent/US20240262877A1/en active Pending
-
2025
- 2025-05-26 JP JP2025086967A patent/JP2025116068A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003527115A (ja) | 2000-03-13 | 2003-09-16 | セント ビンセンツ ホスピタル | 新規のh因子関連タンパク質5及びその抗体 |
| JP2013520979A (ja) | 2010-03-05 | 2013-06-10 | リグショスピタレト | 補体活性化のキメラ抑制分子 |
| WO2018075462A1 (en) | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating and preventing transplant-associated injury |
Non-Patent Citations (2)
| Title |
|---|
| GILMORE C. Alyssa et al.,Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains,Kidney International,2020年10月28日,Vol.99,pp.396-404 |
| HELLWAGE Jens et al.,The human complement regulatory factor-H-like protein 1, which represents a truncated form of factor H, displays cell-attachment activity,Biochem. J.,1997年,Vol.326,pp.321-327 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023014037A (es) | 2024-01-15 |
| EP4347666A1 (en) | 2024-04-10 |
| CN117396519A (zh) | 2024-01-12 |
| WO2022251168A9 (en) | 2023-02-16 |
| CA3177162A1 (en) | 2022-11-25 |
| JP2024520421A (ja) | 2024-05-24 |
| JP2025116068A (ja) | 2025-08-07 |
| KR20240013770A (ko) | 2024-01-30 |
| AU2022283254A9 (en) | 2023-12-07 |
| AU2022283254A1 (en) | 2023-11-30 |
| US20240262877A1 (en) | 2024-08-08 |
| WO2022251168A1 (en) | 2022-12-01 |
| BR112023024627A2 (pt) | 2024-02-20 |
| IL308754A (en) | 2024-01-01 |
| EP4347666A4 (en) | 2025-07-16 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250526 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250526 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260319 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260616 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260706 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260803 |